Page 2 of 4 · 91 questions tagged liver-enzymes.
Baseline ALT was 24 U/L. Fourteen weeks into semaglutide it came back at 41 U/L, still inside the lab's quoted range of 0 to 50 but a 71% rise from where I started. I…
The particulars: AST · survodutide. I would like to define my thresholds before I have a result, for obvious reasons. I want a plan with explicit stopping rules, not…
What I have: ALT · AST · ecnoglutide. Both of these get recommended confidently by different people, which suggests neither is obviously right. My constraints are…
I have the full paper rather than the abstract, and the supplementary appendix. I have the document in front of me and I can read the numbers. What I cannot do is…
The case in front of me: TSH · retatrutide. I can predict the outcome but I cannot explain it, which means I will get the next case wrong. I would like to know how…
The clinician who ordered the panel was not concerned; I would still like to understand it. I would like help reading this properly rather than being told what…
What I am working with: cystatin C · survodutide. I understand the observation; what I do not understand is the mechanism behind it. I have read the two review…
The specifics, since they change the answer: AST · ALT · cagrilintide. The comparison I want does not seem to exist anywhere in a form I can evaluate. I have read the…
Every MASH trial reports large falls in ALT and AST alongside the histological endpoints, and the enzyme falls are usually much more impressive-looking than the…
The specifics, since they change the answer: albumin-to-creatinine ratio · GGT · oral semaglutide. I have used one of these for a while and I am considering…
This is a question about interpretation, not about whether to act — I will take action questions elsewhere. I have read the primary source rather than the summary,…
Setup, so nobody has to ask: ALT · eight weeks · ecnoglutide. I noticed this today and I have not touched anything since, in case the state is diagnostic. I have not…
Stated plainly: cystatin C · ecnoglutide. I understand the observation; what I do not understand is the mechanism behind it. I have read the two review articles that…
Setup, so nobody has to ask: LDL-C · a GLP-1 receptor agonist. I keep seeing this stated as a fact with no explanation attached, and unexplained facts make me…
The specifics, since they change the answer: cystatin C · semaglutide. I understand the observation; what I do not understand is the mechanism behind it. I have read…
Details up front: triglycerides · survodutide. I would like the mechanism, because I want to be able to reason about the cases nobody has written about. I have tried…
Following on from the discussion of sampling variability: if simultaneous biopsies from the same liver disagree by a fibrosis stage in a meaningful fraction of cases,…
The particulars: AST · ecnoglutide. I would like to define my thresholds before I have a result, for obvious reasons. I want a plan with explicit stopping rules, not…
Setup, so nobody has to ask: ALT · a GLP-1 receptor agonist. I am trying to build something sustainable rather than something thorough that I will abandon. I have…
What I have: albumin-to-creatinine ratio · orforglipron. I suspect the usual explanation for this is wrong, or at least incomplete. I am aware this may have a boring…
Details up front: GGT · liraglutide. I want to decide this in advance so that I am not deciding it under pressure later. Assume I will follow the plan I write down,…
Concretely: lipase · mazdutide. The empirical answer seems settled. The explanation does not. If the honest answer is that nobody knows, I would rather hear that than…
What I have: creatinine · cagrilintide. The empirical answer seems settled. The explanation does not. If the honest answer is that nobody knows, I would rather hear…
Conditions: GGT · liraglutide. I want to know whether this is a real physical effect or an artefact of how it is measured. What prompted the question is an…